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Dystrophic epidermolysis bullosa (DEB) is a rare
skin disorder that is clinically heterogeneous and is
transmitted either in dominant (DDEB) or recessive
(RDEB) mode. Nevertheless, all variants of DEB are
caused by mutations in type VII collagen gene
(COL7A1).We report an analysis of COL7A1 mutations
in 51 Italian DEB patients, 27 a¡ected with Hallopeau^
Siemens RDEB, 19 with non Hallopeau^Siemens
RDEB, two with DDEB, two with pretibial RDEB,
and one with inversa RDEB. Forty-one mutations were
identi¢ed, 18 of which are novel. Mutation conse-
quences were analyzed at the mRNA and protein level
and genotype^phenotype correlation was determined.
Recessive inheritance of a new case of pretibial RDEB
was also established. In RDEB patients, six recurrent
mutations were identi¢ed: 7344G-A, 425A-G, 8441^
14del21, 4783^1G-A, 497insA, and G1664A, the last
three being found only in Italian patients. Indeed,
haplotype analysis supported propagation of ancestral
mutated alleles within the Italian population for these
particular mutations. Altogether recurrent mutations
account for approximately 43% of RDEB alleles in Ita-
lian patients and therefore new DEB patients should
¢rst be screened for the presence of these mutations.
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D
ystrophic epidermolysis bullosa (DEB) is a genoder-
matosis inherited either in autosomal dominant or
recessive pattern and characterized by blistering
and scarring of the skin and mucous membranes
(Bruckner-Tuderman et al, 1999). Blistering is due
to defects in anchoring ¢brils (AF), structures mainly composed
of typeVII collagen (COLVII), that maintain adhesion of the epi-
dermis to the dermis (Burgeson, 1993). COLVII is a homo-
trimeric collagen [a1(VII)]3; each chain is synthesized as
a proa1(VII) polypeptide, consisting of a central collagenous do-
main and two £anking amino- and carboxy-terminal non-col-
lagenous domains (NC1 and NC2, respectively) (Christiano et al,
1994a). The proa1(VII) chains are encoded by the COL7A1 gene,
localized on chromosome 3p21 (Christiano et al, 1994b). Linkage
analysis and subsequent mutation analysis have demonstrated that
COL7A1 is the defective gene in all forms of DEB (Ryyn@nen
et al, 1991; J@rvikallio et al, 1997).
DEB is a clinically heterogeneous disorder showing di¡erent
degrees of blistering, scarring, and extracutaneous involvement
(Fine et al, 2000).The phenotypical variability depends on the dif-
ferent type of mutations in DEB alleles and their position within
the gene. From the identi¢cation of an increasing number of mu-
tations, however, some general genotype^phenotype correlation
has been drawn (J@rvikallio et al, 1997; Pulkkinen and Uitto,
1999). Speci¢cally, dominant forms of DEB are typically caused
by glycine substitutions in the collagenous domain (Christiano
et al, 1994c), whereas the most severe type of DEB, the recessive
Hallopeau^Siemens variant (HS-RDEB), is frequently due to the
presence of mutations leading to premature termination codon of
translation (PTC) on both alleles (Hovnanian et al, 1994).
Although in DEB the pathogenic mutations are generally
family speci¢c, some recurrent mutations have been reported in
di¡erent populations: R578X and 7786delG in British patients
(Mellerio et al, 1997), 5818delC and E2857X in Japanese patients
(Tamai et al, 1999), 2470insG in Mexican patients (Salas-Alanis
et al, 2000), as well as 497insA, 4783^1G-A, and 8441^14del21
in Italian patients (Ashton et al, 1999; Gardella et al, 1999).
This study reports the survey of COL7A1 mutations in 51
Italian patients. A total of 41 COL7A1 mutations was character-
ized, 18 of which were novel and six of which were frequent
in this population. Mutation consequences at the mRNA
and protein level are also reported and the genotype^phenotype
correlation is discussed.1RG and DC equally contributed to this work.
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MATERIALS AND METHODS
Immuno£uorescence and electron microscopy studies Skin biop-
sies were obtained from DEB patients and healthy controls and processed
for immuno£uorescence and electron microscopy studies, and for
¢broblast cultures.
Skin cryosections from all patients were immunostained with the
monoclonal antibody LH7:2 (kind gift of I. Leigh, U.K.) directed against
the COLVII NC1 domain.
Skin biopsy specimens were ¢xed in 2% glutaraldehyde, post¢xed in
1% osmium tetroxide, dehydrated in graded alcohols, embedded in Epon
resin, and then sectioned on a Reichert Ultracut E ultramicrotome.
Ultrathin sections were stained with uranyl acetate and lead citrate and
observed in a Philips CM100 transmission electron microscope.
Skin ¢broblasts were grown in vitro at 371C in modi¢ed Eagle’s medium
supplemented with 10% fetal bovine serum, 100 mg per ml penicillin, and
100 mg per ml streptomycin. Human epidermal keratinocytes obtained
from skin biopsies of patients and healthy volunteers were cultivated on a
feeder-layer of lethally irradiated 3T3-J2 murine ¢broblasts (a gift from H.
Green, Harvard Medical School, Boston, MA), as described previously
(Zambruno et al, 1995).
Mutation detection and veri¢cation The search for mutations was
performed on ampli¢ed COLVII mRNA or genomic DNA by
heteroduplex analysis. For this purpose, 3 mg of total RNA puri¢ed from
in vitro cultured ¢broblasts were reverse-transcribed and the cDNA was
ampli¢ed with primers covering the full-length COLVII cDNA sequence,
as previously described (Gardella et al, 1999). One hundred nanograms of
genomic DNA were used as template for polymerase chain reaction
ampli¢cation of COL7A1 exons as described by Christiano et al (1997).
The polymerase chain reactions were analyzed on MDE gels, following
the manufacturer’s protocol (FMC Corporation, Rockland, ME), or by
conformation sensitive gel electrophoresis. The ampli¢ed products
showing heteroduplex bands were subjected to direct automated
sequencing using the Thermo Sequenase dye terminator cycle sequencing
kit (Amersham Biosciences, Little Chalfont, U.K.) and an ABI Prism 377
DNA sequencer (Applied Biosystems, Foster City, CA).
All mutations identi¢ed at cDNA level were checked by sequencing
genomic DNA. Mutation detection was also carried out by restriction
digestion or allele speci¢c ampli¢cation (see also Table III). In particular,
allele speci¢c ampli¢cation for the most frequent 497insA mutation was
carried out using the wildtype primer 50 -CCCAAAGGCTGA-
AGGGGCAG-30 or the mutant primer 50 -CCCAAAGGCTGAAGGGG-
CAA-30 in combination with the primer 50 -AGTCACTGGTGG-
GCTGTGAGG-30 in the following conditions: 941C for 6 min, 28 cycles
at 941C for 30 s, 661C for 20 s, 721C for 30 s, and a ¢nal step at 721C for
5 min.
RESULTS
Clinical ¢ndings Fifty-one Italian unrelated DEB patients,
49 a¡ected with di¡erent variants of RDEB and two with
dominant DEB (DDEB), were studied (Table I). The majority
of the RDEB patients (27) had the Hallopeau^Siemens
mutilating subtype of RDEB (HS-RDEB). Among the 19 non
HS-RDEB cases, eight patients had a severe phenotype with
widespread skin blistering but without pseudosyndactyly or
fusion of the digits (non HS-RDEB gen), and 11 patients had
milder blisters and scarring limited to trauma-exposed sites and,
except one case, no signi¢cant mucosal involvement (non HS-
RDEB loc). Of two patients with the pretibial form of the
disease (Pt-RDEB), one has been already described (Betts et al,
1999) and the other had recurrent blisters on the shins and
associated lichenoid papules since the age of 15 y (Fig 1A).
Finally, one patient had features of inversa RDEB (I-RDEB),
with blister formation in the £exures, in particular axillae, groin,
and intergluteal fold. This patient also had severe esophageal
stenosis.
COL7A1 Italian mutation survey The mutation screening,
performed on ampli¢ed COLVII cDNA or genomic DNA, was
carried out by heteroduplex analysis on MDE gels or by
conformation sensitive gel electrophoresis, with an overall
mutation detection sensitivity of 86%. Forty-one mutations
were identi¢ed: one promoter substitution (2%), abolishing
transcription; and 16 insertion/deletions (39%), six nonsense
(15%), nine missense (22%), and nine splicing mutations (22%)
(Table II). In the patients’ families, 70 molecular analyses for
detection of mutation carriers and four DNA-based prenatal
diagnoses were also performed (Table I).
Novel COL7A1 mutations In the Italian patients analyzed, 18
novel mutations were identi¢ed: 10 insertion/deletions, one
nonsense, ¢ve missense, and two splicing mutations (Tables I,
II). All the novel insertion/deletion mutations led to a frameshift
and to formation of downstream PTCs.
The ¢ve novel missense mutations are all localized in the
collagenous domain and three of them result in glycine
substitutions. In particular, the G1664A mutation is a glycine to
alanine substitution due to the 4991G-C transversion in exon
54. This is a frequent mutation that has been identi¢ed in ¢ve
unrelated RDEB patients, three showing non HS-RDEB gen
phenotype (Table I, patients 28, 29, 33) and two a non HS-
RDEB loc form (patients 42, 45). This glycine substitution is a
recessive mutation, as demonstrated by the absence of DEB
clinical signs in the carriers of the mutation. The G1664A
substitution has also been identi¢ed as a homozygous mutation
in a patient with an extremely mild phenotype comprising only
nail dystrophy, minimal atrophic scars over the extremities, and
no evidence of overt blisters in adulthood (patient 42; Fig 2). In
keeping with these minimal clinical signs, COLVII staining
intensity at the dermal^epidermal junction appeared only slightly
decreased and AF, although reduced in number, still displayed a
clear evidence of central cross-banding (Fig 2).When present in
combination with a PTC mutation, however, the G1664A
mutation leads to a more severe phenotype, with di¡use skin
blisters and mucosal involvement (patients 28, 29), as the PTC
mutation on the second allele prevents expression of full-length
COLVII molecules and only one-half of COLVII molecules, all
carrying the glycine substitution, are synthesized.
The novel G2012S mutation, found in patient 50, is a glycine
to serine substitution due to a 6034G-A transition in exon 73.
As this mutation was not detected in the patient’s parents and
nonpaternity was excluded, it appears to have arisen as a de novo
event. Moreover, no other disease mutations were detected in the
patient. These ¢ndings, taken together with the observation that
most glycine substitutions so far characterized in exon 73 have a
dominant e¡ect (Mecklenbeck et al, 1999), indicate that the
G2012S is a dominant mutation.
A further novel glycine substitution close to the G2012S
mutation, G2070E in exon 74, was identi¢ed in patient 51. This
glycine to glutamic acid substitution, caused by a 6209G-A
transition, has a dominant inheritance, as demonstrated by its
presence in the a¡ected mother of the patient.
Two other novel genetic defects, a P1699L missense and
a 267^1G-C splicing mutation, were found in compound
heterozygosity in a patient with the Pt-RDEB subtype (patient
47). Immuno£uorescence staining of a pretibial lichenoid lesion
showed a slightly reduced COLVII staining and some
intracytoplasmic keratinocyte deposits for COLVII (Fig 1B). By
electron microscopy AF were reduced in number and appeared
much shorter and thinner than normal (Fig 1C). The P1699L
mutation is caused by a C-T transition at position 5096 of
COLVII cDNA, in exon 55. By restriction analysis this mutation
was not found in 104 alleles from una¡ected control subjects, thus
indicating that the P1699L substitution is a disease mutation
rather than a nonpathogenic polymorphism. The 267^1G-C
mutation abolishes the conserved acceptor splice site of intron 2.
Reverse transcription polymerase chain reaction performed on
RNA from patients’ keratinocytes revealed two aberrant
mRNA species, in addition to the normal size mRNA. Direct
sequencing of the aberrant bands identi¢ed an abnormal
mRNA transcript, carrying the out-of-frame deletion of the
entire exon 3, and a second out-of-frame transcript derived from
the use of a cryptic splice site that includes a portion of intron 2
(Fig 1E, F).
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Finally, a novel R2622W substitution, due to a 7864C-T
transition in exon 105, was detected in compound hetero-
zygosity with a novel 2482delCT mutation in a patient a¡ected
with the rare I-RDEB subtype (patient 49).
Recurrent COL7A1 mutations This study has shown the
presence of recurrent COL7A1 mutations in the Italian RDEB
patients consisting of the 497insA (15.3% of the mutated alleles),
4783^1G-A (6.1%), 7344G-A (6.1%), 425A-G (5.1%),
G1664A (5.1%), and 8441^14del21 (5.1%) (Table III). Altogether
these six mutations cover about 43% of RDEB alleles in Italian
patients. In particular, the 497insA insertion mutation has been
found so far only in Italian patients (Christiano et al, 1996b;
Ashton et al, 1999; Gardella et al, 1999). Also the 4783^1G-A
and G1664A mutations have been detected only in Italian
patients. The 8441^14del21 has been found also in a British
Table I. COL7A1 phenotypes and genotypes in DEB Italian patients
Patient no. Diagnosisa AFb COLVIIc Mutation 1 Mutation 2 Consequences
1 HS-RDEB ND ^ ^96C-T R1978X No transcription/PTC
2 HS-RDEB ^ ^ 111insA 497insA PTC/PTC
3 HS-RDEB ^ þ þ þ 344insG R2063W PTC/missense
4 HS-RDEB ^ ^ 425A-G 425A-G PTC/PTC
5 HS-RDEB ^ ^ 497insA 497insA PTC/PTC
6 HS-RDEB ^ ^ 497insA 497insA PTC/PTC
7 HS-RDEB ^ ^ 497insA 497insA PTC/PTC
8 HS-RDEB ^ ^ 497insA 497insA PTC/PTC
9 HS-RDEB ^ ^ 497insA 497insA PTC/PTC
10 HS-RDEB ^ ^ 497insA R226X PTC/PTC
11 HS-RDEB ND ND 497insA 682þ1G-A PTC/PTC
12 HS-RDEBd ND ND 497insA 6501þ1G-T PTC/in-frame skipping
13 HS-RDEB ND ^ 638insA ND PTC/^
14 HS-RDEB ND ^ R226X R226X PTC/PTC
15 HS-RDEB ND ^ R236X R236X PTC/PTC
16 HS-RDEB ^ ^ 806insT 4783^1G-A PTC/PTC
17 HS-RDEBd ND ND 847^6G-A 8505insC PTC/PTC
18 HS-RDEBd ND þ 2587insCC ND PTC/^
19 HS-RDEB ND ND 3148delC ND PTC/^
20 HS-RDEBd ND ND 4783^1G-A 4783^1G-A PTC/PTC
21 HS-RDEB þ þ 4783^1G-A G2351R PTC/missense
22 HS-RDEB ND ND 4783^1G-A 8441^14del21 PTC/PTC
23 HS-RDEB ND ND 4783^1G-A 8441^14del21 PTC/PTC
24 HS-RDEB ^ ^ R2685X R2685X PTC/PTC
25 HS-RDEB þ þ R2685X ND PTC/^
26 HS-RDEB ^ ^ 8074delG 8505insC PTC/PTC
27 HS-RDEB ND ND 8441^14del21 8441^14del21 PTC/PTC
28 non HS-RDEB gen þ þ þ 425A-G G1664A PTC/missense
29 non HS-RDEB gen ND ND 497insA G1664A PTC/missense
30 non HS-RDEB gen þ þ 4172delC ND PTC/^
31 non HS-RDEB gen ND ND 4317delC ND PTC/^
32 non HS-RDEB gen þ þ 4871insC ND PTC/^
33 non HS-RDEB gen ND ND G1664A ND Missense/^
34 non HS-RDEB gen ND ND 8441^14del21 ND PTC/^
35 non HS-RDEB gen þ þ 5820G-A R2492X In-frame skipping-normal/PTC
36 non HS-RDEB loc þ þ þ 425A-G 7344G-A PTC/PTC-normal
37 non HS-RDEB loc þ þ þ 425A-G 7344G-A PTC/PTC-normal
38 non HS-RDEB loc þ þþ R578X 7344G-A PTC/PTC-normal
39 non HS-RDEB loc þþþ þþþ G1347R 5820G-A Missense/in-frame skipping-normal
40 non HS-RDEB loc ND þþ 4834del8 7344G-A PTC/PTC-normal
41 non HS-RDEB loc þþ þþ 4965C-T R2063W PTC-normal/missense
42 non HS-RDEB loc þ þ þþ G1664A G1664A Missense/missense
43 non HS-RDEB loc þþ þþ 7344G-A ND PTC-normal/^
44 non HS-RDEB loc þ þ 7344G-A ND PTC-normal/^
45 non HS-RDEB loc ND ND G1664A ND Missense/^
46 non HS-RDEB loc þþ þþ G2775S ND Missense/^
47 Pt-RDEB þ þþ 267^1G-C P1699L PTC/missense
48 Pt-RDEB þ þþ 33563del14 ND In-frame skipping/^
49 I-RDEB þ þþ 2482delCT R2622W PTC/missense
50 DDEB þ þþþ G2012S (de novo) ^ Missense
51 DDEB þ þþþ G2070E ^ Missense
aHS-RDEB, Hallopeau^Siemens recessive DEB; non HS-RDEB General, generalized RDEB, non Hallopeau^Siemens subtype; non HS-RDEB loc, localized RDEB,
non Hallopeau^Siemens subtype; I-RDEB, inversa RDEB; Pt-RDEB, pretibial RDEB; DDEB, dominant DEB.
bAF detected by transmission electron microscopy of the dermal^epidermal junction: þ þ þ , normal; þ þ, reduced and altered; þ, highly reduced and altered; ,
absent; ND, not determined.
cCOLVII staining intensity by immuno£uorescence with the LH7:2 monoclonal antibody: þ þ þ , normal; þ þ, reduced/altered; þ, highly reduced; , absent; ND,
not determined.
dDNA-based prenatal diagnosis was performed in the patient’s family.
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patient (Dunnill et al, 1996) whereas the 425A-G and the
7344G-A transitions have been observed in patients from
di¡erent geographic areas (Gardella et al, 1996; Cserhalmi-
Friedman et al, 1997; Hammami-Hauasli et al, 1997; Whittock
et al, 1999). In Italian patients, the 4783^1G-A and 8441^14del21
mutations have been found only in families from Sicily, whereas
the G1664A mutation has been detected exclusively in kindred
from Apulia, another southern Italian region.
DISCUSSION
In this study we report molecular analysis of 51 unrelated Italian
families with DEB; this sample includes all patients who so far
have required the molecular characterization, and represents
about one-¢fth of the DEB Italian families included in the Italian
Register of EB (manuscript in preparation). The majority of the
cases investigated (49 patients) were a¡ected by RDEB and in
particular by the severe HS-RDEB form (27 patients). Only
two patients with DDEB were analyzed. The low number of
DDEB patients reported is not representative of the Italian DEB
distribution in which the dominant forms, classi¢ed on the basis
of clinical signs, family history, and ultrastructural and immuno-
£uorescence analysis, are about 40% of the registred DEB cases.
The data reported conform to the general international experi-
ence of the genotype^phenotype correlation in this genoderma-
tosis. In particular, in the HS-RDEB the PTC mutations were
prevalent (46 out of 54 alleles) and present on both alleles in 19
of the 27 patients. In the eight non HS-RDEB patients, display-
ing di¡use skin blisters and mucosal lesions (non HS-RDEB
gen), one PTC mutation was present in compound heterozygos-
ity with either a missense or a splice site or an as yet unidenti¢ed
mutation, in keeping with the markedly reduced level of
Figure1. Pt-DEB patient: clinical and molecular characterization.
(A) Blisters, erosions, and lichenoid papules on the shins. (B) Immuno-
£uorescence of perilesional pretibial skin shows keratinocyte cytoplasmic
deposits and a di¡use reactivity in the dermis, in addition to the expected
linear dermal^epidermal junction labeling. Scale bar: 25 mm. (C) Transmis-
sion electron microscopy of perilesional skin shows a few rudimentaryAFs
(arrowheads). Scale bar: 0.25 mm. (D) Identi¢cation of the paternal splice mu-
tation (267^1G-C) and maternal 5096C-T substitution (P1699L muta-
tion) by DNA sequence analysis. (E) The paternal 267^1G-C mutation
interferes with the normal splicing of exon 3, as shown by 2% gel electro-
phoresis of the cDNA ampli¢ed with primers 50 -CTCTGGAGCAGC-
CAGTGCAC-30 (nucleotides 205^224) and 50 -AGGGTCAGCATTC-
TTGATCC-30 (nucleotides 521^540) (GenBank accession # L02870). The
ampli¢cation reveals two abnormal transcripts of 406 and 176 bp in the
patient’s sample (p), in addition to the expected 336 bp band present in
the control sample (C). (F) E¡ect of the 267^1G-C mutation on exon 3
splicing. The genomic structure of COL7A1 exons 2^4 and the aberrantly
spliced transcripts is represented.
Table II. COL7A1mutation types in Italian DEB patients
Type of mutation Position Reference
Promoter mutation
96C-T Promoter Gardella et al (2000)
Insertion/deletion
111insA Exon 2 Christiano et al (1996b)
344insG Exon 3 Gardella et al (2002)
497insA Exon 4 Christiano et al (1996b)
638insA Exon 5 This study
806insT Exon 6 This study
2482delCT Exon 19 This study
2587insCC Exon 19 This study
3148delC Exon 24 This study
4172delC Exon 36 This study
4317delC Exon 39 Whittock et al (1999)
4834del8 Exon 51 This study
4871insC Exon 51 This study
8074delG Exon 109 This study
8441^14del21a Intron 114/exon 115 Dunnill et al (1996)
8505insC Exon 115 This study
33563del14 (8523del14)
a,b Exon 115/intron 115 Bruckner-Tuderman et al (1995)
Nonsense mutationsb
R226X (676C-T) Exon 5 Christiano et al (1996b)
R236X (706C-T) Exon 6 Hovnanian et al (1994)
R578X (1732C-T) Exon 13 Dunnill et al (1994)
R1978X (5932C-T) Exon 72 Gardella et al (2000)
R2492X (7474C-T) Exon 98 This study
R2685X (8053C-T) Exon 109 Gardella et al (1999)
Missense mutations
G1347R (4039G-C) Exon 34 Terracina et al (1998)
G1664A (4991G-C) Exon 54 This study
P1699L (5096C-T) Exon 55 This study
G2012S (6034G-A) Exon 73 This study
R2063W (6187C-T) Exon 74 Hovnanian et al (1997)
G2070E (6209G-A) Exon 74 This study
G2351R (7051G-A) Exon 91 Christiano et al (1996a)
R2622W (7864C-T) Exon 105 This study
G2775S (8323G-A) Exon 112 Kon et al (1998)
Splicing mutations
267^1G-C Exon 2 This study
425A-G Exon 3 Gardella et al (1996)
682þ1G-A Intron 5 Hovnanian et al (1997)
847^6G-A Intron 7 Whittock et al (1999)
4783^1G-A Intron 49 Ashton et al (1999)
4965C-T Exon 53 Gardella et al (2002)
5820G-A Exon 70 Terracina et al (1998)
6501þ1G-T Intron 79 This study
7344G-A Exon 95 Gardella et al (1996)
aDeletion mutation leading to aberrant splicing.
bThe nucleotide change in COLVII cDNA sequence (accession no. L02870) is
indicated in parentheses.
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COLVII immunostaining detected by immuno£uorescence ana-
lysis of skin biopsies. On the other hand, eight of the 11 non HS-
RDEB patients showing a milder phenotype (non HS-RDEB
loc) harbored splicing mutations that allow the maturation of a
portion of full-length COLVII mRNA molecules encoding for
functional proa1(VII) chains (Gardella et al, 1996; 2002; Terracina
et al, 1998). These splicing mutations were found in combination
with a PTC or a missense mutation. Finally, one patient with an
extremely mild non HS-RDEB loc phenotype was homozygous
for the G1664A missense mutation. Together with the clinical
¢ndings, the slightly reduced COLVII staining and the presence
of numerous cross-banded AF at the dermal^epidermal junction
indicate that the recessive G1664A missense mutation has a mild
e¡ect on COLVII triple helix folding as well as on COLVII secre-
tion and supramolecular assembly in AFs. This may re£ect the
change from glycine to alanine, another small non-pda amino
acid, or the actual position of the substitution within the triple
helix.
This study also included three patients with rare variants of
DEB (Fine et al, 2000), the pretibial and inversa DEB forms, cur-
rently classi¢ed as dominantly and recessively inherited, respec-
tively. The two Pt-RDEB patients, one novel and the other one
previously described (Betts et al, 1999), represent the only two
clear cases in which an autosomal recessive inheritance pattern
has been established, although Mellerio et al (1999) reported a
compound heterozygote (7786delG/5532þ1G-A) who had
DEB pruriginosa but clinical features most apparent on the shins.
Together with a few autosomal dominant cases previously re-
ported (Lee et al, 1993; Christiano et al, 1995), our data support
the notion that Pt-DEB can be either dominantly or recessively
inherited. In particular, the new Pt-RDEB patient is a compound
heterozygote for a 267^1G-C splice mutation, which leads to
two aberrant out-of-frame transcripts undergoing mRNA decay,
and a P1669L missense mutation. The P1699L mutation was not
found in 52 control DNAs and involves a proline residue con-
served among type VII collagen in human, mouse, and hamster.
This proline is located in a collagenous subdomain at theY posi-
tion of a Gly-X-Y repeat. Proline residues at the Y position are
frequently hydroxylated to 4-hydroxyproline and are involved
in stabilization of collagen triple helices (Tasanen et al, 2000). In-
deed, the cytoplasmic COLVII labeling observed in our patient’s
skin suggests that the P1669L mutation interferes with COLVII
folding and/or secretion. In addition, substitutions a¡ecting pro-
line residues have recently been identi¢ed as disease mutations in
three RDEB patients (Ryyo et al, 2001).
The I-RDEB patient here described was a compound hetero-
zygote for a 2482delCT PTC mutation and an R2622Wmissense
mutation localized in proximity to the end of the collagenous
domain, at the third position of a Gly-X-Ymotif. Arginine is an
aliphatic and hydrophilic and positively charged amino acid pre-
sent at the third position in 70% of the Gly-X-Y motifs in the
COL7A1 triple helix collagenous domain. Tryptophan is a larger
aromatic and hydrophobic amino acid absent in the collagenous
domain, with the only exception of a residue in the 39 amino
acid Gly-X-Y interruption. It is therefore conceivable that repla-
cement of the arginine with tryptophan signi¢cantly alters the
conformation of COLVII molecules, thus impairing triple helix
and/or AF assembly. In two other patients, another recessive argi-
nine to tryptophan substitution, the R2063W, also localized in
the collagenous domain, at the third position of a Gly-X-Y motif
was detected. One patient a¡ected with HS-RDEB was a com-
pound heterozygote for the R2063W and the 344insG mutation,
whereas another patient, a¡ected with non HS-RDEB loc, was a
compound heterozygote for the R2063W and the 4965C-T
splicing mutation (Gardella et al, 2002). As either the 2622 and
the 2063 arginine residues are conserved in human, mouse, and
hamster COLVII, they should lie in COLVII critical regions. In
Figure 2. Molecular characterization of a non HS-RDEB patient
with an extremely mild and localized phenotype (patient 42 inTable
I). (A) Transmission electron microscopy shows the presence of numerous
cross-banded AF at the dermal^epidermal junction of the patient (arrows).
Scale bar: 0.5 mm. (B) DNA sequence analysis shows a homozygous G-C
transversion in the patient, leading to a Gly 1664 to Ala substitution,
G1664A.
Table III. COL7A1 recurrent mutations in Italian RDEB patients
Mutation Number of mutated alleles % of mutated alleles Italian geographic origin Detection method Reference
497insA 15 15.3 Widespread ASAa Gardella et al (1999)
4783^1G-A 6 6.1 Sicily Eco57I/SAb Ashton et al (1999)
7344G-A 6 6.1 Widespread HphI Gardella et al (1996)
425A-G 5 5.1 Widespread StyI Gardella et al (1996)
G1664A 5 5.1 Apulia PstI This study
8441^14del21 5 5.1 Sicily SA Ashton et al (1999)
aAllele speci¢c ampli¢cation.
bSequence analysis.
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particular, the R2063 arginine lies in the middle of the collage-
nous domain, close to the carboxy-terminus of the Gly-X-Y in-
terruption. This interruption, called ‘‘hinge’’, is thought to be
crucial for the function of COLVII molecules, conferring £ex-
ibility to the triple helix. This could explain the more severe ef-
fect of the R2063W compared to the R2622W substitution,
which should be located in a less critical position. Interestingly,
it has been observed that the substitution of the arginine at posi-
tion 2063 with a glycine, the smallest amino acid, is less deleter-
ious than the substitution with tryptophan, as compound
heterozygosity for the R2063G mutation and the R236X PTC
mutation results in an inversa nHS-RDEB (Hovnanian et al, 1997).
Overall, about 25% of the 41 mutations reported in this study
are splicing mutations a¡ecting the transcription and processing
of COLVII mRNA. This percentage is higher than that reported
for most human genes (10%^15%) and is likely to re£ect the pre-
sence of the large number of exons (118) in COL7A1 (Christiano
et al, 1994b).
Concerning the distribution of the mutations along COL7A1,
three of nine missense mutations occurred in exons 73^74 and
one of these (G2012S) represented a de novo event. Indeed, exon
73 has previously been shown to harbor a large number of gly-
cine substitutions, including several de novo mutations (Rouan
et al, 1998; Mecklenbeck et al, 1999; Whittock et al, 1999; Nordal
et al, 2001;Wessagowit et al, 2001).
The survey of the Italian RDEB patients here reported has
shown the presence of six recurrent mutations in COL7A1. In
particular, the insertion 497insA is the most frequent in Italian
patients. Haplotype analysis performed on DNA from all Italian
patients carrying this mutation, by PvuII and AluI intragenic
polymorphisms and by £anking polymorphic microsatellites, in-
dicated a common origin for this mutation and the propagation
of an ancestral mutant allele (Ashton et al, 1999; Gardella et al,
1999;data not shown). Moreover, two common Italian mutations,
4783^1G-A and the G1664A, show a regional distribution, as
they were found in patients from Sicily and Apulia, respectively.
Also for these mutations, detected only in Italian patients, haplo-
type analysis and their regional distribution indicate a common
ancestral origin. Altogether, the six frequent mutations were
found in 43% of the RDEB alleles and therefore Italian RDEB
patients should be ¢rst screened for these mutations. When fre-
quent mutations are not identi¢ed, mutation detection analysis
should be extended to the entire COLVII cDNA by heteroduplex
analysis, and when needed the more sensitive DHPLC and
sequencing analysis should be performed. This strategy should
be applied in the search for mutations in Italian DEB patients
requiring COL7A1 molecular characterization, also in view of
genetic counseling and DNA-based prenatal diagnosis.
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